Online inquiry

IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12511MR)

This product GTTS-WQ12511MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MUC5AC gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001304359.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4586
UniProt ID P98088
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12511MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13343MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ4911MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ8763MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ825MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ8293MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ7638MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ9162MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ2064MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW